Clinical Trials Directory

We are doing this study to better understand women's preferences for and concerns about hormone replacement. We want to learn from women who have had their fallopian tubes and ovaries removed due to BRCA1 and BRCA2 mutations.

We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.

We are doing this study to find out if an experimental drug called zifibancimig (the study drug) is a safe and effective option for people with neovascular age-related macular degeneration (nAMD). We want to see how well it works in comparison to ranibizumab, which is an FDA-approved drug for the treatment of nAMD. Both the study drug and approved drug that are used in this study are given as eye implants.

We are doing this study to determine if long-term treatment with camizestrant after surgery is a safe and effective option for treating patients with early-stage ER+/HER2- breast cancer. We want to compare the outcomes of using camizestrant to current standard of care treatments (endocrine therapy).

We are doing this study to compare different approaches aimed at preventing strokes for people who have already had a stroke. We want to know what combination of drugs seems to have the best outcomes when it comes to stroke prevention.

We are doing this study to find out if an experimental drug called eplontersen (the study drug) is safe and helpful for people with cardiac amyloidosis. We are enrolling people who previously participated in a clinical trial for this drug called the CardioTTRansform study (ION-682884-CS2).

We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.

We are doing this study to see how different things, like medical and treatment history, affect outcomes in people with cardiac amyloidosis.